Innovative approaches to the therapy of fibrosis
- 1 November 2009
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 21 (6) , 649-655
Abstract
Purpose of review The lung in systemic sclerosis (scleroderma) is susceptible to fibrosis and the ensuing respiratory insufficiency contributes to significant morbidity and mortality in this disease. The lack of effective therapies for pulmonary fibrosis has spurred a re-evaluation of pathobiological paradigms and therapeutic strategies in scleroderma-associated interstitial lung disease and in idiopathic pulmonary fibrosis. The purpose of this review is to examine emerging new therapeutic targets that modulate pro-fibrotic phenotypes of tissue-resident cells and the associated aberrant tissue remodeling responses in fibrotic disorders. Recent findings Progressive forms of tissue fibrosis, including scleroderma, are characterized by an accumulation of activated mesenchymal cells and their secreted extracellular matrix proteins in association with dysrepair of epithelial and endothelial cells. Recent studies suggest that emergence of cellular phenotypes that perpetuate loss of cellular homeostasis is characteristic of many fibrosis-related clinical syndromes. Summary Therapeutic strategies that modulate the fate/phenotype of reparative structural cells, including epithelial, endothelial, and mesenchymal cells, offer new opportunities for the development of more effective drugs for the treatment of fibrosis.Keywords
This publication has 80 references indexed in Scilit:
- NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injuryNature Medicine, 2009
- Nontoxic Chemical Interdiction of the Epithelial-to-Mesenchymal Transition by Targeting Cap-Dependent TranslationACS Chemical Biology, 2009
- Short telomeres are a risk factor for idiopathic pulmonary fibrosisProceedings of the National Academy of Sciences, 2008
- Isolation of an Adult Mouse Lung Mesenchymal Progenitor Cell PopulationAmerican Journal of Respiratory Cell and Molecular Biology, 2007
- Rho Kinase (ROCK) InhibitorsJournal of Cardiovascular Pharmacology, 2007
- Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injuryProceedings of the National Academy of Sciences of the United States of America, 2007
- Effects of the Protein Kinase Inhibitor, Imatinib Mesylate, on Epithelial/Mesenchymal Phenotypes: Implications for Treatment of Fibrotic DiseasesThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Combinatorial activation of FAK and AKT by transforming growth factor-β1 confers an anoikis-resistant phenotype to myofibroblastsCellular Signalling, 2007
- A pure population of lung alveolar epithelial type II cells derived from human embryonic stem cellsProceedings of the National Academy of Sciences, 2007
- Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrixProceedings of the National Academy of Sciences, 2006